Additional Information

Description

Flucelvax® 2025–2026 (Flu-108) is a cell-based quadrivalent influenza vaccine intended for active immunization against influenza A and B virus strains expected during the 2025–2026 influenza season. Unlike egg-based vaccines, it is manufactured using Madin-Darby Canine Kidney (MDCK) cells, which helps avoid egg-adapted mutations and may provide a closer antigenic match to circulating strains.

The vaccine is supplied as a 5 mL multi-dose vial, containing ten 0.5 mL doses. It is approved for individuals aged 6 months and older. Each dose is administered intramuscularly, typically into the deltoid muscle in adults and older children or into the anterolateral thigh in infants. Flucelvax® does not contain a live virus and cannot cause influenza illness. 

Common adverse effects include injection site pain, swelling, redness, muscle aches, headache, and fatigue. Fever, irritability, and malaise may occur in younger populations. Rare but serious risks include hypersensitivity reactions and Guillain-Barré syndrome. The vaccine is contraindicated in individuals with a history of severe allergic reaction to any vaccine component.